Genome-wide gene expression profiles of thyroid carcinoma: Identification of molecular targets for treatment of thyroid carcinoma

Oncology Reports

Volumn 20, Issue 1, 2008, Pages 105-121

  Nikolova, Dragomira Nikolaeva ^a,b   Zembutsu, Hitoshi ^a   Sechanov, Tanio ^b   Vidinov, Kalin ^b   Kee, Low Siew ^a   Ivanova, Radina ^b   Becheva, Elitza ^b   Kocova, Miriana ^c   Toncheva, Draga ^b   Nakamura, Yusuke ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^c SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

Author keywords

Gene expression profile; Microarray; Molecular target gene; Thyroid carcinoma

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; FIBRONECTIN; FIBRONECTIN 1; RGS4 PROTEIN; SMALL INTERFERING RNA; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; RGS PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CARCINOGENESIS; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER MICROBEAM MICRODISSECTION; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CARCINOMA; UNINDEXED SEQUENCE; DRUG ANTAGONISM; GENETICS; MIDDLE AGED; THYROID TUMOR; TUMOR CELL LINE;

ADULT; AGED; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; RGS PROTEINS; RNA, SMALL INTERFERING; THYROID NEOPLASMS;

EID: 49849097645     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.20.1.105     Document Type: Article

References (63)

1. Hundahl SA, Fleming ID, Fremgen AM and Menck HR: A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 83: 2638-2648, 1998.
2. Mazzaferri EL and Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418-428, 1994.
3. Kebebew E and Reiff E: Patients with differentiated thyroid cancer have a venous gradient in thyroglobulin levels. Cancer 109: 1078-1081, 2007.
4. Eszlinger M, Krohn K, Frenzel R, Kropf S, Tonjes A and Paschke R: Gene expression analysis reveals evidence for inactivation of the TGF-beta signaling cascade in autonomously functioning thyroid nodules. Oncogene 23: 795-804, 2004.
5. Yano Y, Uematsu N, Yashiro T, Hara H, Ueno E, Miwa M, Tsujimoto G, Aiyoshi Y and Uchida K: Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res 10: 2035-2043, 2004.
6. Lubitz CC, Ugras SK, Kazam JJ, Zhu B, Scognamiglio T, Chen YT and Fahey TJ III: Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J Mol Diagn 8: 490-498, 2006.
7. Baris O, Mirebeau-Prunier D, Savagner F, Rodien P, Ballester B, Loriod B, Granjeaud S, Guyetant S, Franc B, Houlgatte R, Reynier P and Malthiery Y: Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma. Oncogene 24: 4155-4161, 2005.
8. Lubitz CC, Gallagher LA, Finley DJ, Zhu B and Fahey TJ III: Molecular analysis of minimally invasive follicular carcinomas by gene profiling. Surgery 138: 1042-1048, 2005.
9. Montero-Conde C, Martin-Campos JM, Lerma E, Gimenez G, Martinez-Guitarte JL, Combalia N, Montaner D, Matias-Guiu X, Dopazo J, de Leiva A, Robledo M and Mauricio D: Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene 27: 1554-1561, 2008.
10. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS and de la Chapelle A: Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 98: 15044-15049, 2001.
11. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH and McMillan A: Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms. World J Surg 30: 767-774, 2006.
12. Sunde M, McGrath KC, Young L, Matthews JM, Chua EL, Mackay JP and Death AK: TC-1 is a novel tumorigenic and natively disordered protein associated with thyroid cancer. Cancer Res 64: 2766-2773, 2004.
13. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K and Joensuu H: Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 9: 68-75, 2003.
14. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, Tamaoki N, Nomura T, Kitahara O, Yanagawa R, Hirata K and Nakamura Y: Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 62: 518-527, 2002.
15. Shimokawa T, Furukawa Y, Sakai M, Li M, Miwa N, Lin YM and Nakamura Y: Involvement of FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta catenin/T-cell factor complex. Cancer Res 63: 6116-6120, 2003.
16. Rufini V, Castaldi P, Treglia G, Perotti G, Gross MD, Al-Nahhas A and Rubello D: Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother Aug 20 Epub ahead of print, 2007.
17. Lundgren CI, Delbridg L, Learoyd D and Robinson B: Surgical approach to medullary thyroid cancer. Arq Bras Endocrinol Metab 51: 818-824, 2007.
18. Huang CL, Sun L, Moonga BS and Zaidi M: Molecular physiology and pharmacology of calcitonin. Cell Mol Biol 52: 33-43, 2006.
19. Nishidate T, Katagiri T, Lin ML, Mano Y, Miki Y, Kasumi F, Yoshimoto M, Tsunoda T, Hirata K and Nakamura Y: Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol 25: 797-819, 2004.
20. Griffith OL, Melck A, Jones SJ and Wiseman SM: Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 24: 5043-5051, 2006.
21. Jarzab B and Wiench M: Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 65: 1587-1597, 2005.
22. Gupta GP, Perk J, Acharyya S, de Candia P, Mittal V, Todorova-Manova K, Gerald WL, Brogi E, Benezra R and Massagué J: ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci USA 104: 19506-19511, 2007.
23. Asirvatham AJ, Carey JP and Chaudhary J: ID1-, ID2-, and ID3-regulated gene expression in E2A positive or negative prostate cancer cells. Prostate 67: 1411-1420, 2007.
24. Rodda S, Sharma S, Scherer M, Chapman G and Rathjen P: CRTR-1, a developmentally regulated transcriptional repressor related to the CP2 family of transcription factors. J Biol Chem 276: 3324-3332, 2001.
25. Arnaldi LA, Borra RC, Maciel RM and Cerutti JM: Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid 15: 210-221, 2005.
26. Puskas LG, Juhasz F, Zarva A, Hackler L Jr and Farid NR: Gene profiling identifies genes specific for well differentiated epithelial thyroid tumors. Cell Mol Biol 51: 177-186, 2005.
27. Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA and Fahey TJ III: Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 9: 1792-1800, 2003.
28. Eszlinger M, Krohn K, Kukulska A, Jarzab B and Paschke R: Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. Endocr Rev 28: 322-338, 2007.
29. Gubala E, Wiench M, Oczko-Wojciechowska M, Lange D, Wloch J, Czarniecka A, Chmielik E, Nikiel B, Wygoda Z, Kukulska A, Handkiewicz-Junak D, Szpak-Ulczok S, Krawczyk A, Roskosz J and Jarzab B: Gene expression analysis by DNA microarray in papillary thyroid cancer. Endokrynol Pol 56: 752-757, 2005.
30. Siraj AK, Bavi P, Abubaker J, Jehan Z, Sultana M, Al-Dayel F, Al-Nuaim A, Alzahrani A, Ahmed M, Al-Sanea O, Uddin S and Al-Kuraya KS: Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J Pathol 213: 190-199, 2007.
31. Finley DJ, Arora N, Zhu B, Gallagher L and Fahey TJ III: Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89: 3214-3223, 2004.
32. Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, Davuluri RV, de la Chapelle A and Eng C: Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22: 3531-3539, 2004.
33. Qian Z, Okuhara D, Abe MK and Rosner MR: Molecular cloning and characterization of a mitogen-activated protein kinase-associated intracellular chloride channel. J Biol Chem 274: 1621-1627, 1999.
34. Tenta R, Katopodis H, Chatziioannou A, Pilalis E, Calvo E, Luu-The V, Labrie F, Kolisis F and Koutsilieris M: Microarray analysis of survival pathways in human PC-3 prostate cancer cells. Cancer Genomics Proteomics 4: 309-318, 2007.
35. Foltz G, Ryu GY, Yoon JG, Nelson T, Fahey J, Frakes A, Lee H, Field L, Zander K, Sibenaller Z, Ryken TC, Vibhakar R, Hood L and Madan A: Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res 66: 6665-6674, 2006.
36. Chevillard S, Ugolin N, Vielh P, Ory K, Levalois C, Elliott D, Clayman GL and El Naggar AK: Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res 10: 6586-6597, 2004.
37. Finley DJ, Zhu B, Barden CB and Fahey TJ III: Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 240: 425-436, 2004.
38. Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK and Costourous N: Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 64: 2898-2903, 2004.
39. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A and Kloos RT: Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18: 48-57, 2005.
40. Tseleni-Balafouta S, Gakiopoulou H, Fanourakis G, Voutsinas G, Balafoutas D and Patsouris E: Tenascin-C protein expression and mRNA splice variants in thyroid carcinoma. Exp Mol Pathol 80: 177-182, 2006.
41. Kebebew E, Peng M, Reiff E and McMillan A: Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer 106: 2592-2597, 2006.
42. Hölting T, Siperstein AE, Clark OH and Duh QY: Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol 132: 229-235, 1995.
43. Haugen DR, Akslen LA, Varhaug JE and Lillehaug JR: Demonstration of a TGF-alpha-EGF-receptor autocrine loop and c-myc protein over-expression in papillary thyroid carcinomas. Int J Cancer 55: 37-43, 1993.
44. Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, Sueyoshi K, Aikou T and Sato E: Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 31: 428-433, 2000.
45. Collet JF, Hurbain I, Prengel C, Utzmann O, Scetbon F, Bernaudin JF and Fajac A: Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples. Br J Cancer 93: 1175-1181, 2005.
46. Asp J, Thornemo M, Inerot S and Lindahl A: The helix-loop-helix transcription factors Id 1 and Id 3 have a functional role in control of cell division in human normal and neoplastic chondrocytes. FEBS Lett 438: 85-90, 1998.
47. Norton JD: ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 113: 3897-3905, 2000.
48. Massari ME and Murre C: Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol 20: 429-440, 2000.
49. Deleu S, Savonet V, Behrends J, Dumont JE and Maenhaut C: Study of gene expression in thyrotropin-stimulated thyroid cells by cDNA expression array: ID3 transcription modulating factor as an early response protein and tumor marker in thyroid carcinomas. Exp Cell Res 279: 62-70, 2002.
50. Chan AS, Tsui WY, Chen X, Chu KM, Chan TL, Chan AS, Li R, So S, Yuen ST and Leung SY: Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma. Oncogene 22: 6946-6953, 2003.
51. Mineva I, Gartner W, Hauser P, Kainz A, Löffler M, Wolf G, Oberbauer R, Weissel M and Wagner L: Differential expression of alphaB-crystallin and Hsp27-1 in anaplastic thyroid carcinomas because of tumor-specific alphaB-crystallin gene (CRYAB) silencing. Cell Stress Chaperones 10: 171-184, 2005.
52. C Köhrle J: Thyroid hormone transporters in health and disease: advances in thyroid hormone deiodination. Best Pract Res Clin Endocrinol Metab 21: 173-191, 2007.
53. Ward LS, Brenta G, Medvedovic M and Fagin JA: Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clin Endocrinol Metab 83: 525-530, 1998.
54. Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C and Eng C: Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res 63: 2864-2871, 2003.
55. Huang Y, de la Chapelle A and Pellegata N: Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer 104: 735-744, 2003.
56. Visconti R, Federico A, Coppola V, Pentimalli F, Berlingieri MT, Pallante P, Kruhoffer M, Orntoft TF and Fusco A: Transcriptional profile of Ki-Ras-induced transformation of thyroid cells. Cancer Invest 25: 256-266, 2007.
57. Branet F, Caron P, Camallières M, Selves J and Brousset P: Bcl-2 proto-oncogene expression in neoplastic and non neoplastic thyroid tissue. Bull Cancer 83: 213-217, 1996.
58. Ros P, Rossi DL, Acebrón A and Santisteban P: Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis. Biochimie 81: 389-396, 1999.
59. Cherian MG, Jayasurya A and Bay BH: Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 533: 201-209, 2003.
60. Albig AR, Neil JR and Schiemann WP: Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 66: 2621-2629, 2006.
61. Dhanabal M, LaRochelle WJ, Jeffers M, Herrmann J, Rastelli L, McDonald WF, Chillakuru RA, Yang M, Boldog FL, Padigaru M, McQueeney KD, Wu F, Minskoff SA, Shimkets RA and Lichenstein HS: Angioarrestin: an antiangiogenic protein with tumor-inhibiting properties. Cancer Res 62: 3834-3841, 2002.
62. Tomida M: Structural and functional studies on the leukemia inhibitory factor receptor (LIF-R): gene and soluble form of LIF-R, and cytoplasmic domain of LIF-R required for differentiation and growth arrest of myeloid leukemic cells. Leuk Lymphoma 37: 517-525, 2000.
63. Tatenhorst L, Senner V, Püttmann S and Paulus W: Regulators of G-Protein Signaling 3 and 4 (RGS3, RGS4) are associated with Glioma Cell Motility. J Neuropathol Exp Neurol 63: 210-222, 2004.